Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients

Journal of Experimental & Clinical Cancer Research, Jun 2010

Background To determine the expression of bone morphogenetic protein-2 (BMP-2) and its receptors BMPRIA, BMPRIB, and BMPRII in epithelial ovarian cancer (EOC) and to analyze their influence on the prognosis of ovarian cancer patients. Methods Semi-quantitative RT-PCR and western blot were applied to detect the expression of BMP-2 and its receptors BMPRIA, BMPRIB, and BMPRII in EOC, benign ovarian tumors, and normal ovarian tissue at the mRNA and protein levels. Immunohistochemistry was used to determine the expression of BMP-2 and its receptors in 100 patients with EOC to analyze their influence on the five-year survival rate and survival time of ovarian cancer patients. Results (1) The mRNA and protein expression levels of BMP-2, BMPRIB, and BMPRII in ovarian cancer tissue were remarkably lower than those in benign ovarian tumors and normal ovarian tissue, while no significant differences in BMPRIA expression level was found among the three kinds of tissues. (2) The five-year survival rate and the average survival time after surgery of EOC patients with positive expression of BMP-2, BMPRIB, and BMPRII were remarkably higher than those of patients with negative expression of BMP-2, BMPRIB, and BMPRII. BMPRIA expression was not associated with the five-year survival rate or with the average survival time of ovarian cancer patients. Conclusions BMP-2, BMPRIB, and BMPRII exhibited low expression in EOC tissue, and variation or loss of expression may indicate poor prognosis for ovarian cancer patients.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

http://www.jeccr.com/content/pdf/1756-9966-29-85.pdf

Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients

Journal of Experimental & Clinical Cancer Research REexseparcrhession of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients Ying Ma 0 Lin Ma 0 Quan Guo 0 Shulan Zhang 0 0 Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University , Shenyang 110004 , China Background: To determine the expression of bone morphogenetic protein-2 (BMP-2) and its receptors BMPRIA, BMPRIB, and BMPRII in epithelial ovarian cancer (EOC) and to analyze their influence on the prognosis of ovarian cancer patients. Methods: Semi-quantitative RT-PCR and western blot were applied to detect the expression of BMP-2 and its receptors BMPRIA, BMPRIB, and BMPRII in EOC, benign ovarian tumors, and normal ovarian tissue at the mRNA and protein levels. Immunohistochemistry was used to determine the expression of BMP-2 and its receptors in 100 patients with EOC to analyze their influence on the five-year survival rate and survival time of ovarian cancer patients. Results: (1) The mRNA and protein expression levels of BMP-2, BMPRIB, and BMPRII in ovarian cancer tissue were remarkably lower than those in benign ovarian tumors and normal ovarian tissue, while no significant differences in BMPRIA expression level was found among the three kinds of tissues. (2) The five-year survival rate and the average survival time after surgery of EOC patients with positive expression of BMP-2, BMPRIB, and BMPRII were remarkably higher than those of patients with negative expression of BMP-2, BMPRIB, and BMPRII. BMPRIA expression was not associated with the five-year survival rate or with the average survival time of ovarian cancer patients. Conclusions: BMP-2, BMPRIB, and BMPRII exhibited low expression in EOC tissue, and variation or loss of expression may indicate poor prognosis for ovarian cancer patients. - Background Ovarian cancer is the most lethal type of malignant tumors of the female reproductive system, and despite recent developments in diagnosis and treatment techniques, the five-year survival rate for ovarian cancer patients is only 20-40%[1]. The low survival rate is likely due to the lack of early symptoms for this cancer; most patients are diagnosed at an advanced stage and exhibit widespread metastasis. At present, the pathological causes of ovarian cancer are unclear. Thus, it is urgent to investigate and search for novel treatment regimens. The development of tumors is believed to be a complex process involving several genes and several factors, and more and more influencing factors are emerging. In recent years, researchers have focused on the correlation between bone morphogenetic proteins (BMPs) and the presence of tumors. BMP is a member of the transforming growth factor- superfamily. Initially, it was thought to induce bone formation and chondrogenesis in vivo, and current evidence suggests that it also participates in various biological processes of cells, such as proliferation, differentiation, and apoptosis[2]. BMP signaling is mediated by transmembrane serine/threonine kinases, namely, BMPRI (BMPRIA, BMPRIB) and BMPRII receptors[3]. There are 16 kinds of BMPs, and the majority of studies have focused on BMP-2, which has been shown to play a crucial role in the occurrence and development of breast cancer[4-6], lung cancer[7-11], prostatic carcinoma[12-14], and colon cancer[15,16]. However, the correlation between BMP-2 and ovarian cancer remains unclear. This study was designed to determine the expression of BMP-2 and its receptors in epithelial ovarian cancer, benign ovarian tumors, and normal ovarian tissue and to analyze their influence on the five-year survival rate and average survival time of ovarian cancer patients. RT-PCR samples: A total of 29 EOC patients, 32 benign ovarian tumor patients, and 10 patients with normal ovarian tissue were recruited from Shengjing Hospital, which is affiliated with China Medical University, between August 2005 and August 2007. Western blot samples: A total of 15 EOC patients, 15 benign ovarian tumor patients, and 10 patients with normal ovarian tissue were recruited from Shengjing Hospital, which is affiliated with China Medical University, between August 2005 and August 2007. Immunohistochemistry samples: One hundred paraffin-embedded specimens of EOC preserved at the Department of Pathology of Shengjing Hospital between January 1997 and August 2001 were included in this study. Specimens were examined for histological grade based on World Health Organization criteria. All EOC patients were grade II and grade III. The tumor stages were determined according to the International Federation of Gynecology and Obstetrics (FIGO) with surgically and cytologically stage performed, all EOC patients had stage III and stage IV. All specimens were fixed with paraformaldehyde, embedded in paraffin, and prepared as serial slices of 4 m in thickness. All experiment subjects had complete (...truncated)


This is a preview of a remote PDF: http://www.jeccr.com/content/pdf/1756-9966-29-85.pdf

Ying Ma, Lin Ma, Quan Guo, Shulan Zhang. Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients, Journal of Experimental & Clinical Cancer Research, 2010, pp. 85, 29, DOI: 10.1186/1756-9966-29-85